Side-by-side · Research reference
Kisspeptin-10vsLL-37
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED10/41 cited
BHuman-MechanisticHUMAN-REVIEWED15/35 cited
Kisspeptin-10
Neuropeptide · GPR54 Agonist
Phase 1/2Clinical stage
IV / SQ · Investigational
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
01Mechanism of Action
Parameter
Kisspeptin-10
LL-37
Primary target
GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026Collado-Sole 2026
Pathway
Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026Rønnekleiv 2026
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Downstream effect
Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Feedback intact?
Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026Rønnekleiv 2026
—
Origin
C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Antibody development
—
—
02Dosage Protocols
Parameter
Kisspeptin-10
LL-37
Clinical trial dose
Phase 1/2 investigational
Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).
—
Route
IV or SQ administration
IV preferred in controlled trials for precise pulsatile delivery.
—
Evidence basis
Phase 1/2 trials
In vitro, animal models, human observational
Half-life
Short (minutes)
Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.
—
Endogenous expression
—
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
Exogenous (experimental)
—
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
04Side Effects & Safety
Parameter
Kisspeptin-10
LL-37
Ovarian hyperstimulation
Theoretical risk with supraphysiological dosing in fertility protocols
—
Headache
Mild, reported in early-phase trials
—
Nausea
Transient GI symptoms with IV bolus
—
Hot flashes
Vasomotor symptoms from LH surge
—
Injection site reaction
Erythema, mild discomfort (SQ route)
—
Cytotoxicity (high dose)
—
Membrane disruption in host cells at supraphysiological concentrations
Pro-inflammatory signaling
—
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
Theoretical cancer risk
—
Immunomodulatory roles in tumor microenvironment under investigation
Absolute Contraindications
Kisspeptin-10
- ·Active pregnancy
- ·Hormone-sensitive malignancy (breast, ovarian, endometrial)
LL-37
—Relative Contraindications
Kisspeptin-10
- ·Polycystic ovary syndrome (PCOS) without monitoring
- ·Uncontrolled thyroid dysfunction
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
05Administration Protocol
Parameter
Kisspeptin-10
LL-37
1. Reconstitution (if lyophilized)
Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
2. Route selection
IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
3. Timing
Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
4. Monitoring
Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.
—
5. Storage
Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.
—